ABSTRACT Background: Guidelines on the diagnosis and treatment of iron deficiency (ID) vary widely across indications. Objective: We reviewed all available guidelines on the management of ID worldwide. Design: A literature search was conducted in PubMed, Cochrane, and EMBASE and in main professional association websites, limited to documents published between 1 January 2004 and 30 June 2014. Results: Of 127 guidelines identified, 29 were selected, involving 29 professional associations and issued from the United States (n = 8), Europe (n = 6), Britain (n = 4), Canada (n = 3), international organizations (n = 2), France (n = 2), Poland (n = 1), Australia (n = 1), Mexico (n = 1), and Japan (n = 1). A total of 22 and 27 guidelines provided recommendations on diagnosis and treatment of ID, respectively. To define ID, all guidelines recommended a concentration for serum ferritin. One-half of them (10 of 22) proposed transferrin saturation (TSAT) as an alternative or complementary diagnostic test. To treat ID, most of the guidelines (18 of 27) recommended preferentially the oral route if possible, particularly in children and in women in the pre-or postpregnancy period. Iron supplementation should be administered intravenously according to 13 of 27 guidelines, particularly in patients with chronic kidney disease (CKD) (n = 7) and chemotherapy-induced anemia (n = 5). Treatment targets for ID included an increase in hemoglobin concentrations to 10-12 g/dL or normalization (n = 8) and serum ferritin .100 mg/L (n = 7) or 200 mg/L (n = 4). For the latter, in some situations, such as CKD, ferritin concentrations should not exceed 500 mg/L (n = 5) or 800 mg/L (n = 5). Only 9 guidelines recommended TSAT as a target, proposing various thresholds ranging from 20% to 50%. Conclusions: It appears that for the diagnosis of ID, a cutoff of 100 mg/L for serum ferritin concentration should be considered in most conditions and 20% for TSAT, except in particular situations, including young healthy women with heavy menstrual flow. New indications of intravenous iron supplementation are emerging. Am J Clin Nutr 2015;102:1585-94.
INTRODUCTION
Iron deficiency (ID) 8 is the most common and widespread nutritional disorder in the world; 2 billion people-.30% of the world's population-are anemic, many because of ID (1, 2) . ID is the only nutrient deficiency that is also prevalent in industrialized countries (1) , particularly in women of childbearing age with heavy menstrual flow and miscarriages. In clinical practice, several chronic conditions are also associated with ID.
ID, with or without anemia, is a common complication of cancers (42.6% across different tumors) (3) . ID is also frequent in inflammatory bowel disease (IBD) (45%) (4), chronic kidney disease (CKD) (24-85%) (5), chronic heart failure (CHF) (43-100%) (6, 7) and other chronic inflammatory diseases. ID may be absolute when the total body iron stock is low (i.e., after hemorrhages). Functional ID occurs when the iron is not able to go out of the macrophages trapped in macrophages, in the reticuloendothelial system (RES), with as consequence a kinetic imbalance between the increased iron demand of the stimulated erythroid marrow and iron supply. In functional ID, iron is therefore sequestered in the reticuloendothelial system (among which are the Kupffer cells). The hepatocytes comprise relatively low iron concentrations in this condition (i.e., IBD, CKD, and many other inflammatory situations).
ID is associated with impaired quality of life (8) , work productivity (9) , and fatigue (10) . There is also a strong relation between iron status and depression and cognitive functioning (11) . Furthermore, ID is a strong predictor of mortality in CHF (7) and CKD (12, 13) . Hence, diagnosing and treating ID with or without anemia is a major issue in clinical practice.
Several diagnostic tests and definitions of ID have been proposed so far. In 2001, the WHO defined ID with thresholds of serum ferritin concentrations varying according to sex, age, and the infectious context (14) . However, this definition is inadequate in many clinical situations, including inflammation and CKD, in which ferritin concentrations tend to increase, and thus are falsely normal when associated with ID (12, 15) . Moreover, definitions and recommendations proposed by the WHO were focused on ID in children and women during the perigestational period, a major public health problem throughout the world. Treating ID leads to better outcomes, including scores of self-reported Patient Global Assessment and those of the New York Heart Association, and quality of life in patients with New York Heart Association functional class II or III CHF (16) .
Over the past decade, professional associations for each specialty have developed their own guidelines. Accordingly, recommendations for treating ID vary across indications. Herein, we review available definitions of ID across indications and current recommendations on the diagnosis and management of ID in human diseases before giving some recommendations for clinical practice based on the available evidence.
METHODS

Literature search strategy
A literature search was conducted in PubMed, EMBASE, Cochrane, and main professional association websites, including those of the WHO and the National Institute for Health and Care Excellence (NICE) and those of each concerned medical specialty, such as cardiology, nephrology, oncology-hematology, orthopedics, anesthesiology, and obstetrics-gynecology, issued from any country worldwide. We used the following search terms: "Anemia" (MeSH) or "Anemia, iron deficiency" (MAJR), and "iron" and ["deficiency" or "ferritin" or "definition", "diagnosis", "supplementation" or "treatment" or "transferrin saturation" (TSAT) or "TSAT" or "soluble transferrin receptor" (sTfR) or "sTfR"].
Selection criteria
Only guidelines focusing on diagnosis and/or management of ID in healthy or ill patients (both adults and children) were selected. The search was limited to English-and French-language documents published between 1 January 2004 and 30 June 2014. Only the last update of guidelines was included in this article. Three independent researchers (LP-B, NW, and PC) screened retrieved citations and abstracts to select titles for the full-text article. All citations whose abstract or full text was not available were excluded.
Data collection
Information on thresholds of ferritin and/or transferrin saturation for the diagnosis of ID was extracted from each included article. If available, the preferential route of iron supplementation, objectives of treatment, and/or target values of ferritin, TSAT, and/or hemoglobin were also collected. We also identified new biomarkers of iron status, such as sTfR.
RESULTS
Literature search results
A total of 107 guidelines from the past decade were identified in PubMed, EMBASE, and Cochrane with the use of the search keywords listed above ( Figure 1) . After reviewing the title and/ or the abstract of the 107 guidelines that were identified with the predefined search terms, a total of 26 guidelines were included in the systematic review. By searching on the websites from the professional associations of each specialty, 20 additional guidelines were selected, including a 2014 update of the National Comprehensive Cancer Network focused on the management of chemotherapy-induced anemia and 2 referral guidelines issued from general medical websites such as those of the NICE and the American Academy of Family Physicians. Of these 46 guidelines selected, 10 duplicates were excluded (because only the last update was included in the systematic review) and 7 articles were excluded because the full text was not available. Thus, a total of 29 guidelines were included in this systematic review: British (n = 5) (17-21), American (n = 7) (22-28), European (n = 9, including 2 French, 1 Polish, and 6 European societies) (4, (29) (30) (31) (32) (33) (34) (35) (36) , Canadian (n = 3) (37-39), Australian (n = 1) (40), Mexican (n = 1) (41), and Japanese (n = 1) (42) recommendations. Some professional associations and experts worked together to provide international recommendations (n = 2) (43, 44) through an article focused on the treatment of ID in IBD (n = 1) (43) or CKD (45) . Overall, 29 professional associations provided recommendations on the diagnosis and treatment of ID, whether in the general population (n = 4) (17, 18, 27, 40) or in 9 specific conditions (n = 54), including CKD (n = 8) (18, 19, 26, 32, 38, 39, 42, 45) , chemotherapy-induced anemia (n = 5) (24, 25, 30, 31, 34) , the perigestational period (n = 4) (21, 35, 36, 41) , children (n = 3) (17, 23, 37) , digestive diseases (n = 3) (4, 43, 46) , IBD (n = 2) (4, 43), heart diseases (n = 2) (28, 33), severe perioperative bleeding (n = 1) (29) , and preoperative anemia in elective orthopedic surgery patients (n = 1) (22 Twenty-two guidelines provided recommendations on ID diagnosis ( Table 1) , whereas 27 were on the modalities of treatment of ID ( Table 2 ). It is noteworthy that 18 guidelines reported the level of evidence, including guidelines on anesthesia (n = 1) (29), heart diseases (n = 2) (28, 33) , digestive diseases (n = 3) (4, 43, 46) , CKD (n = 6) (18, 21, 39, 42, 44, 45) , and chemotherapy-induced anemia (n = 2) (3, 34).
Diagnosis of ID
To define ID (Table 1) , all guidelines recommended the measurement of serum ferritin concentrations. One-half of them (10 of 22) proposed TSAT as an alternative or complementary diagnostic test (4, 18, 19, 22, 25, 32, 42, 43, 45, 47) . Four guidelines (18, 20, 23, 35) mentioned the potential diagnostic role of sTfR, especially in children ,3 y of age (23, 35) and women in the perigestational period (23, 35) . Only 1 of these 4 guidelines specified a threshold in pregnant women (18) for sTfR, and one other did not recommend its routine use because of lack of supportive evidence (18) . A decrease in mean corpuscular volume (,80 fL), an increase in total iron-binding capacity (.68 mmol/L) or hypochromic red cells (+6%), and a low reticulocyte hemoglobin content (,29 pg) may also support diagnosis of ID, as mentioned in some guidelines (18, 19, 40) . The clinical utility of plasma erythropoietin and/or hepcidin has yet to be determined (18) .
Eight guidelines took into account the presence of an inflammatory syndrome when interpreting ferritin concentration, which may be falsely normal despite a low iron store (4, 14, (19) (20) (21) (22) (23) 43 ). Indeed it is well known that this clinical situation defines functional ID, as opposed to absolute ID. Functional ID is mainly observed during infection, active inflammatory disorders such as IBD, and chemotherapy-induced anemia. Two guidelines defined the anemia of chronic disease, including IBD, and proposed thresholds for ferritin and TSAT to distinguish functional ID from absolute ID (4, 43) .
Ferritin concentration to define ID
According the NHANES, ferritin references range from 30 to 400 mg/L for men and from 13 to 150 mg/L for women. Several thresholds were proposed for the diagnosis of ID with the use of ferritin concentrations across specialties and indications.
The 12-15-mg/L threshold for ferritin was proposed in 10 guidelines, including those in the general population (n = 4) (17, 18, 40, 46) , women (n = 3) (21, 35, 38) , children (n = 3) (17, 23, 37) , and patients with CKD (n = 2) (18, 38) or digestive diseases (n = 1) (46) .
The 25-30-mg/L threshold for ferritin was proposed in 9 guidelines for the general population (n = 3) (22, 29, 43) , IBD (n = 2) (4, 43), CKD (n = 3) (38, 45, 47) , chemotherapyinduced anemia (n = 1) (25) , and the perigestational period (n = 1) (21). Of note, when referring to the general population (22, 29, 43) , all patients either had a chronic disease such as inactive IBD or were in the particular situation of perioperative bleeding.
The 45-50-mg/L threshold for ferritin was proposed in 3 guidelines, and involved the general population (n = 2) (17, 27) with a diagnosis of ID that was estimated as "probable," as well as digestive diseases (n = 1) (46).
The 100-mg/L threshold for ferritin was proposed in 12 guidelines, mainly in the context of CKD (n = 5) (18, 19, 32, 42, 45) , in the general population (n = 2) (17, 18), for which the diagnosis of ID is estimated as "possible" with the use of this cutoff, in patients with heart disease (n = 2) (28, 33), in active IBD (n = 2) (4, 43), and for anesthesia (n = 2) (22, 29) .
The 200-mg/L threshold for ferritin was proposed in 2 guidelines, exclusively for patients with hemodialysis CKD who are receiving hemodialysis (18, 32) . The 500-mg/L threshold for ferritin was proposed in 1 guideline focusing on patients with CKD (45) .
The 800-mg/L threshold for ferritin, which defines functional ID, was proposed in 2 guidelines for chemotherapy-induced anemia (n = 1) (25) and CKD, whether hemodialyzed or not (n = 1) (18) . For functional ID, ferritin concentration is usually between 100 and 800 mg/L and TSAT is between 30% and 50% (25) .
TSAT to define ID
With respect to TSAT, about one-half of selected guidelines (10 of 22) proposed various thresholds.
Three guidelines proposed the 15-16% threshold for TSAT; indications included IBD (n = 2) (4, 43), CKD (n = 1) (26), and the general population (n = 1) (43) .
Seven guidelines proposed the 20% threshold for TSAT in CKD (n = 5) (19, 22, 32, 42, 45) , the general population (n = 2) (18, 22) , children (n = 1) (45), and IBD (n = 1) (4).
Other guidelines proposed higher thresholds for TSAT, such as 25% (n = 1) (18) and 30% (n = 1) (45) in patients with CKD, whether undergoing hemodialysis or not. The highest threshold was reported in the situation of functional ID in chemotherapyinduced anemia, because TSAT may rise to 50% (ferritin between 30 and 800 mg/L) in these patients (n = 1) (25).
Treatment of ID
Oral compared with intravenous route of administration
Of the 27 guidelines focusing on the treatment of ID (Table 2) , all indicated the preferential route for iron supplementation (oral or intravenous). Most of these guidelines (18 of 27) (4, 17, 19, 21-23, 26, 27, 29, 32, 36, 37, 39-41, 43, 45, 46) recommended the oral route as a first-line treatment for ID. The intravenous route was proposed as an alternative in case of inefficiency, intolerance, or malabsorption of iron salts. This is particularly true in CKD (n = 5) (19, 26, 32, 39, 45) , in the general population (n = 4) (17, 22, 27, 40) , in women in the perigestational period (n = 3) (21, 36, 41) , and in IBD (n = 2) (4, 43).
Intravenous iron supplementation only was recommended in 13 guidelines (18, 19, 24, 25, 28, 30, 31, 33, 34, 39, 42, 45, 47) , particularly in chemotherapy-induced anemia (n = 5) (24, 25, 30, 31, 34) in the case of either absolute or functional ID. Indeed, in this indication, the oral route of iron supplementation is no more effective than placebo. The context of heart disease requires a quick correction of anemia without exposing patients to the risk of transfusion associated circulatory overload. Also, the intravenous route (n = 2) (28, 33), appears the preferential route in this context and in patients with CKD, according to Japanese CKD guidelines (n = 1) (42), particularly in patients with hemodialysis.
The oral route was recommended in 7 guidelines for the treatment of ID in children (n = 2) (23, 37), the pre-or postpregnancy situation (n = 3) (21, 36, 41) , CKD (n = 1) (45), and the general population (n = 1) (27) .
Treatment targets of ID: hemoglobin, ferritin, and/or TSAT Of the 13 guidelines reporting the target value of hemoglobin (Table 2) (24, 25, 30, 31, 34) , nephrology (n = 2) (19, 32), and pregnancy (n = 1) (41). Other guidelines, mainly for nephrology and pediatrics, recommended an increase in hemoglobin concentrations of +1-2 g/dL monthly as a therapeutic target (n = 2) (19, 23). Some restrictive strategies recommend a hemoglobin concentration .7 g/dL in the particular situation of severe perioperative bleeding and in case of heart failure because of the risk of volumetric overload related to intravenous iron supplementation (28, 29) . Regarding ferritin, 6 of 11 guidelines focused on patients with CKD (19, 26, 32, 39, 45, 47) , 1 focused on patients with heart disease (28), 1 focused on IBD (43), 2 focused on chemotherapyinduced anemia (25, 34) , and 1 focused on pregnancy (36 (26, 32, 42) . In this situation, oral iron supplementation remains an option if the dose is adapted (26, 32) .
Of the 9 guidelines recommending TSAT as a target (19, 26, 32, 34, 39, 42, 43, 45, 48) , 6 proposed exceeding the TSAT threshold by 20% (19, 26, 34, 39, 42, 45) , and 1 proposed exceeding it by 30% (32) . Only 3 guidelines defined a maximum threshold of 50% (25, 42, 43) , particularly in patients with CKD (n = 1) (42), IBD (n = 1) (43), or chemotherapy-induced anemia (n = 1) (25) . Only one guideline focused on the general population and did not recommend a TSAT rate for assessing therapy response, but only ferritin concentration (18) .
DISCUSSION
ID is one of the leading risk factors for disability and death worldwide, affecting an estimated 2 billion people (48) .
All guidelines recommend measuring ferritin concentrations for the diagnosis of ID. The main advantages of this test are its accessibility, its cost, and especially its sensitivity to variations of the iron store in case of ID, iron overload, or during normalization (on iron supplementation). However, it is well established that serum ferritin concentrations may increase in the event of inflammation, liver or muscular cytolysis, decompensated diabetes, chronic alcoholism, hyperthyroidism, macrophage activation syndrome, and certain metabolic syndromes (49) . Of note, the only cause of low ferritin serum concentration is ID. Reference values for serum ferritin also vary depending on age and sex, especially in children and pregnant women. Over the various medical situations, the definition of ID and its range of approaches appears unclear because studies were performed in different laboratories and at different times in previous decades, and there has been variation and evolution in assay techniques and platforms (50) . Only one review, including studies published before 1988, recommended cutoffs that were proposed by the second and third WHO International Standards: ferritin can effectively rule out ID anemia in patients with or without inflammatory disease at cutoffs of 70 and 40 mg/L, respectively (51) . Accordingly, in our systematic review, ranges of ferritin defining ID varied across studies from 12 to 200 mg/L for absolute ID and from 100 to 800 mg/L for functional ID. Overall, a serum ferritin concentration cutoff of 100 mg/L should be considered in current practices and further clinical trials to define an ID in most conditions. Indeed, at a cellular level, the cell cannot make ferritin unless cellular iron is present, which is why a cutoff of 100 is effective.
TSAT was proposed as an alternative or complementary diagnostic test for ID by 45.5% (10 of 22) of guidelines. TSAT reflects iron availability for erythropoiesis (18) . TSAT decrease is one of the earliest biomarkers of ID, whether absolute or functional. Its main advantage is a normal range that is narrower (between 20% and 40% in adults) than that of ferritin, which is attributable to lower physiologic variation (18) . In our systematic review, the TSAT threshold for the diagnosis of ID ranged from 15% to 25%. This threshold was broadly similar for absolute and functional ID. Seven of 10 guidelines recommending TSAT for ID diagnosis proposed 20% as a threshold for TSAT in CKD (n = 5), the general population (n = 2), children (n = 1), and IBD (n = 1). TSAT alone cannot differentiate absolute ID from functional ID. Functional ID is defined by serum ferritin concentrations .100 mg/L and TSAT ,20%, whereas absolute ID is defined by serum ferritin concentrations ,100 mg/L and TSAT ,20%.
Other diagnostic tests have been proposed for ID diagnosis. Hepcidin, a small peptide produced by the liver, has hyposideremic properties by blocking ferroportin transporter activity. Its activity in normal individuals is increased in the setting of inflammation/infection, which also limits its utility (52, 53) . In contrast, sTfR, a fragment of the membrane receptor, varies independently of inflammation and has been described as a useful marker in patients with absolute ID (increased sTfR concentration) or functional ID (normal sTfR). The sTfR concentration correlates with the expression of the transferrin receptor on the erythroblast membrane. sTfR tends to be elevated in patients treated with an erythropoiesis-stimulating agent by increasing the total erythroblast mass (54) , which limits its use in patients with CKD and those treated for chemotherapy-related anemia. Its concentration is less accurate than ferritin concentrations (55) because of variable sensitivity and a specificity of 70-81% or 59-71% based on a cutoff of 1.5 mg/L or 2.6 mg/L, respectively, in patients with CKD (55, 56) . Furthermore, sTfR testing is not widely available and is not reimbursed in France. One of the problems of sTfR and hepcidin might also be their lack of standardization, which precludes the assessment of uniform clinical decision limits. Only 7 guidelines mentioned hepcidin and sTfR tests (18, 19, 23, 35, 40, 46) .
Regarding treatment of ID, oral supplementation remains the first-line treatment, according to most of the guidelines (18 of 27) because of safety concerns with intravenous supplementation (57) . Two main drugs are commonly used for oral iron supplementation, i.e., ferrous sulfate and ferrous fumarate. The advantages of these drugs are their availability, low cost, and safety. Surprisingly, the oral route is also recommended in patients with functional ID, i.e., CKD (19, 26, 32, 39, 45) , and IBD (4, 43) . However, in such conditions, as well as in many other conditions where chronic inflammation is present, negative hepcidin feedback on the ferroportin transporter blocks the absorption of iron by the digestive tract (53) and the release of iron from macrophages. Hepcidin has been described as a useful marker to predict the efficacy and safety of oral iron supplementation (58) . Moreover, the oral route is often poorly tolerated, with an oral iron malabsorption reported in more than 90% of cases. Thus, adherence to oral iron treatment is poor. The possibility that intestinal inflammation will worsen with oral iron is also debated (59) . Oral heme iron polypeptide is a newer form that has been reported to have higher bioavailability and fewer side effects than nonheme iron in healthy subjects, but data in patients with chronic conditions such as CKD are limited (60) .
Several intravenous preparations are available, such as iron isomaltoside, ferric carboxymaltose, ferric gluconate, ferric sucrose, ferumoxytol, and low-molecular-weight iron dextran. In chemotherapy-induced anemia, several clinical trials demonstrated the superiority of the intravenous route over the oral route (61, 62) . Of note, the latter proved to be as effective as a placebo in these patients (63) . The other advantages of the intravenous route compared with the oral route are its good tolerability in terms of gastrointestinal symptoms (61, 62) , good adherence, and its rapid contribution of a large amount of iron. The main limit of the intravenous route is the risk of anaphylactic reactions whose gravity may be variable. There is a plethora of laboratory and animal data to suggest that intravenous iron can exacerbate oxidative stress and potentiate infections. There are also observational studies that suggest an increased HR for all-cause, cardiovascular, and infection-related mortality, although there are other observational studies that do not show any increased risk. Data from randomized controlled trials are very sparse, particularly with regard to hard clinical endpoints. The amount of intravenous iron that can be safely administered is also not clear, and the traditional biomarkers of iron status, such as serum ferritin and transferrin saturation, are not particularly helpful in this regard. Manifestations of organ dysfunction as seen in High Iron Fe (HFE)-hereditary hemochromatosis, a genetic condition of iron overload, is believed to be rare, but it is possible that patients receiving HD do not live long enough to develop this. Hypersensitivity reactions may occur with all intravenous iron preparations, but are extremely rare now that the high-molecularweight iron dextran compound is no longer available. Randomized controlled trials are urgently required to address the shortfall in the evidence base. One such trial, Proactive IV irOn therapy for HaemodiALysis patients (64) , is already well under way. The study is recruiting 2080 patients receiving maintenance hemodialysis across .50 sites in the United Kingdom who are being randomly assigned to a high-dose or a low-dose intravenous iron regimen with a planned follow-up of between 2 and 4 y. Hard clinical endpoints such as death, myocardial infarction, stroke, heart failure, and infections will be assessed.
In the meantime, nephrologists would do well to recognize both the benefits and the limitations of intravenous iron therapy pending further robust scientific data. The cost-benefit ratio of these drugs is an issue that should be analyzed.
The application of recommendations is not simple in daily clinical practice. For example, although intravenous iron supplementation is recommended in IBD patients in most guidelines, current German practice still relies on oral therapy, even in patients with severe anemia (65) . Targets for concentrations of hemoglobin, ferritin, and TSAT after iron supplementation have not been specified in most guidelines. When a target for hemoglobin concentrations is proposed, it could appear surprisingly low-i.e., hemoglobin .7 g/dL (28) or .10 g/dL (41) . Only 2 clinical situations are relatively well defined by the guidelines, i.e., chemotherapy-induced anemia and CKD. In all other clinical situations for which no target concentration is specified in guidelines, it seems logical to maintain iron supplementation until a return to reference values for ferritin and TSAT. In obese patients and during bariatric surgery, except for the recommendations of the Spain Anemia Working Group (66) , there have been no guidelines issued from any international professional association. Also, mechanisms of ID in these patients are complex and not fully understood (67) . Pending an international consensus, some tools have been specifically developed for the management of ID, such as the website iron.therapy.org, which is reporting expert opinions sponsored by Vifor Pharma and could be helpful in clinical practice to guide decision making. To better define the optimal cutoff for diagnosis of ID and the need to treat these patients, it is important to consider the impact of ID on disease and patient-related outcomes. In this regard, intervention studies should be conducted in other conditions. Also, large prospective cohort studies should be initiated to investigate the correlation between different cutoffs for ferritin concentration and TSAT and disease course (e.g., hospitalizations, morbidity, health-related quality of life, and mortality, among others) in patients with ID.
In conclusion, diagnosing and treating ID is a challenge in clinical practice. Over the past decade, 29 guidelines were published by professional associations worldwide. By reviewing all these guidelines, we found significant heterogeneity on the management (diagnosis and treatment) of ID across indications. Some tools have been specifically developed for the management of ID, such as the website iron. therapy.org, and could be helpful in clinical practice to guide decision making.
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